1. First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide. Issue 8 (21st April 2022) Authors: Pan, Calvin Q.; Afdhal, Nezam H.; Ankoma‐Sey, Victor; Bae, Ho; Curry, Michael P.; Dieterich, Douglas; Frazier, Lynn; Frick, Andrew; Hann, Hie‐Won; Kim, W. Ray; Kwo, Paul; Milligan, Scott; Tong, Myron J.; Reddy, K. Rajender Journal: Hepatology communications Issue: Volume 6:Issue 8(2022) Page Start: 1881 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. (June 2019) Authors: Lik Yuen Chan, Henry; Lampertico, Pietro; Buti, Maria; Fung, Scott; Ahn, Sang Hoon; Chuang, Wan-Long; Tak, Won Young; Ramji, Alnoor; Chen, Chi-Yi; Tam, Edward; Bae, Ho; Ma, Xiaoli; Flaherty, John; Gaggar, Anuj; Lau, Audrey; Feierbach, Becket; Wu, George; Suri, Vithika; Subramanian, Mani; Trinh, Huy Journal: Gut Issue: Volume 68(2019)Supplement 1 Page Start: A142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. (18th November 2020) Authors: Yuen Chan, Henry Lik; Lampertico, Pietro; Ahn, Sang Hoon; Fung, Scott; Bae, Ho; Ramji, Alnoor; Lee, Jung Sung; Shafran, Stephen; Gordon, Stuart; Phan, Charles; Tan, Susanna; Flaherty, John; Gaggar, Anuj; Wu, George; Suri, Vithika; Lau, Daryl; Byun, Kwan Soo; Agarwal, Kosh; Lim, Young-Suk; Buti, M... Journal: Gut Issue: Volume 69(2020)Supplement 2 Page Start: A74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. (September 2016) Authors: Ahn, Joseph; Lim, Joseph K; Lee, Hannah M; Lok, Anna S; Nguyen, Mindie; Pan, Calvin Q; Mannalithara, Ajitha; Te, Helen; Reddy, Rajender K.; Trinh, Huy; Chu, Danny; Tran, Tram; Lau, Daryl; Leduc, Truong‐Sinh; Min, Albert; Le, Loc Trong; Bae, Ho; Van Tran, Sang; Do, Son; Hann, Hie‐Won L Journal: American journal of gastroenterology Issue: Volume 111:Number 9(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. (May 2020) Authors: Lampertico, Pietro; Buti, Maria; Fung, Scott; Ahn, Sang Hoon; Chuang, Wan-Long; Tak, Won Young; Ramji, Alnoor; Chen, Chi-Yi; Tam, Edward; Bae, Ho; Ma, Xiaoli; Flaherty, John F; Gaggar, Anuj; Lau, Audrey; Liu, Yang; Wu, George; Suri, Vithika; Tan, Susanna K; Subramanian, G Mani; Trinh, Huy Journal: Lancet gastroenterology and hepatology Issue: Volume 5:Number 5(2020) Page Start: 441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗